Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 8, 2007, Pages 415-422

  Reyes Gordillo, Karina ^a   Muriel, Pablo ^a   Castañeda Hernández, Gilberto ^a   Favari, Liliana ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Carbon tetrachloride; Diclofenac; Liver injury; Liver regeneration; Necrosis; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; CARBON TETRACHLORIDE; DICLOFENAC; GAMMA GLUTAMYLTRANSFERASE; NAPROXEN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; LIVER FUNCTION; LIVER INJURY; LIVER NECROSIS; LIVER REGENERATION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; WISTAR RAT;

ADMINISTRATION, ORAL; ALANINE TRANSAMINASE; ALPHA-FETOPROTEINS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; CARBON TETRACHLORIDE POISONING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DICLOFENAC; GUANOSINE TRIPHOSPHATE; HALF-LIFE; HEPATITIS, TOXIC; INJECTIONS, INTRAVENOUS; LIVER FUNCTION TESTS; LIVER REGENERATION; MALE; RATS; RATS, WISTAR;

EID: 36448949474     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.569     Document Type: Article

References (47)

1. Brogden RN, Heel RC, Pakes GE, Speight TM, Avery GS. Diclofenac sodium: A review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. Drugs 1980; 20: 24-48.
2. Hinz B, Chevts J, Renner B, et al. Bioavailability of diclofenac potassium at low doses. Br J Clin Pharmacol 2005; 59: 80-86.
3. Zuckner J. International experience with diclofenac in rheumatoid arthritis. Am J Med 1986; 80: 39-42.
4. Scholer D, Ku E, Boettcher I, Schweizer A. Pharmacology of diclofenac sodium. Am J Med 1986; 80: 34-38.
5. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet 1997; 33: 184-213.
6. Rohekar G, Bookman AAM. Diclofenac sodium in the treatment of osteoarthritis. Aging Health 2006; 2: 179-187.
7. Davies NM, Anderson KE. Clinical pharmacokinetics of naproxen. Clin Pharmacokinet 1997; 32: 268-293.
8. Rivera-Espinosa L, Muriel P, Ordaz Gallo M, Pérez-Urizar J, Palma-Aguirre A, Castañeda-Hernández G. Ketorolac pharmacokinetics in experimental cirrhosis by bile duct ligation in the rat. Ann Hepatol 2003; 2: 175-181.
9. Davies NM. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 1998; 34: 101-154.
10. Davies NM, Skjodt NM. Clinical pharmacokinetics of lornoxicam: a short half-life oxicam. Clin Pharmacokinet 1998; 34: 421-428.
11. Bauer LA. Drug dosing in special populations: Renal and hepatic disease, dialysis, heart failure, obesity and drug interaction. In Applied Clinical Pharmacokinetics, Bauer LA (ed.). McGraw Hill: Washington, 2001; 50-66.
12. Verbeeck RK, Horsmans Y. Effects of hepatic insufficiency on pharmacokinetics and drug dosing. Pharm World Sci 1998; 20: 183-192.
13. Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Saf 1997; 17: 47-73.
14. Hay K, Jenny H, Ledikwe BS, Smiciklas H. Nutrition and aging: drug-nutrient interactions. Penn State Nutrition and Extension Partnership Project 2001; 1: 1-9.
15. Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S. Dose adjustment in patients with liver diseases. Drug Saf 2005; 28: 529-545.
16. Lill J, O'Sullivan T, Bauer LA, et al. Pharmacokinetics of diclofenac sodium in chronic active hepatitis and alcoholic cirrhosis. J Clin Pharmacol 2000; 40: 250-257.
17. McLean AJ, Morgan DJ. Clinical pharmacokinetics and pharmacodynamics considerations in patients with liver disease. An update. Clin Pharmacokinet 1995; 29: 370-391.
18. Rithers R, Strandness E, Lau H, Chan K, Thakker K. Pharmacokinetics of diclofenac sodium in chronic active hepatitis and alcoholic cirrhosis. J Clin Pharmacol 2000; 40: 250-257.
19. McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991; 21: 42-69.
20. Favari L, Castañeda G, Hoyo C. Pharmacokinetics and pharmacodynamics of naproxen in acute experimental hepatitis. Arzneimittelforsch Drug Res 1993; 43: 6-10.
21. Fausto N, Laird AD, Webber EM. Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J 1995; 9: 1527-1536.
22. Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997; 276: 60-66.
23. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanisms of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 2003; 33: 105-136.
24. Taniguchi M, Takeuchi T, Nakatsuka R, Watanabe T, Sato K. Molecular process in acute liver injury and regeneration induced by carbon tetrachloride. Life Sci 2004; 75: 1539-1549.
25. Tian H, Ou J, Strom SC, Venkataramanan R. Pharmacokinetics of tacrolimus and mycophenolic acids are altered, but recover at different times during hepatic regeneration in rats. Drug Metab Dispos 2005; 33: 329-335.
26. Galtier M, Briand D, Pinguet F, Gomeri R, Fabre D, Bressole F. Pharmacokinetic parameters of antipyrine in dog after hepatectomy. Biopharm Drug Dispos 1995; 16: 669-684.
27. 4-intoxicated rats. Biol Pharm Bull 1995; 18: 251-255.
28. Granados-Soto V, López FJ, Hong E, Flores FJ. Relationship between pharmacokinetics and the analgesic effect of ketorolac in the rat. J Pharmacol Exp Ther 1995; 272: 352-356.
29. Glossman M, Neville DM. Glutamyl transferase in kidney brush border membranes. FEBS Lett 1972; 19: 340-344.
30. Reitman S, Frankel S. A colorimetric method for determination of serum oxaloacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957; 28: 56-63.
31. Torres-López JE, López J, Castañeda G, Flores FJ, Granados V. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of diclofenac in the rat. J Pharmacol Exp Ther 1997; 282: 685-690.
32. Rosen HR, Keeffe EB. Evaluation of abnormal liver enzymes, use of liver test, and the serology of viral hepatitis. In Liver Disease Diagnosis and Management, Bacon BR, Di Bisceglie AM (eds). Churchill: New York, 2000; 24-35.
33. Muriel P. Nitric oxide protection of rat liver from lipid peroxidation, collagen accumulation, and liver damage induced by carbon tetrachloride. Biochem Pharmacol 1998; 56: 773-779.
34. Becker F. Regeneration of the mammalian liver. In The Liver Normal and Abnormal Functions, Arias MI, Jakoby W, Popper H, Schachter D, Popper H, Shafridz AD (eds). Dekker: New York, 1970; 833-849.
35. Rodighiero V. Effects of liver disease on pharmacokinetics. An Update. Clin Pharmacokinet 2000; 37: 399-431.
36. Kohli R, Harris DC, Whitington PF. Relative elevations of serum alanine and aspartate aminotransferase in muscular dystrophy. J Pediatr Gastroenterol Nutr 2005; 41: 121-124.
37. Villanueva A, Lanuza A, Pérez V, Ceres L, Cortina H, Mari A. Hepatic hematoma in a newborn. Pediatr Radiol 1980; 9: 111-112.
38. Reyes SV, Villalobos MR. Patterns of adrenoceptor change during liver regeneration of the Wistar Kyoto rat: A binding study. Arch Med Res 1999; 30: 89-92.
39. Schmidt LE, Dalhoff K. Alpha fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology 2005; 41: 26-31.
40. Taira Z, Yabe K, Hamaguchi Y, et al. Effects of Sho-saiko-to extract and its components. Baicalin, baicalein glycyrrhizin and glycyrrhetic acid, on pharmacokinetic behavior of salicylamide in carbon tetrachloride intoxicated rats. Food Chem Toxicol 2004; 42: 803-807.
41. Schiodt FV, Ostapowicz G, Murray N, et al. Alphafetoprotein and prognosis in acute liver failure. Liver Transpl 2006; 12: 1776-1781.
42. Kenji T, Kiyoshi Y, Takako F, Terumichi N. Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portalvenous blood concentrations of diclofenac. Pharm Res 1995; 12: 880-883.
43. Tang W, Stearns RA, Wang RW, Chiu SH, Baillie TA. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem Res Toxicol 1999; 12: 192-199.
44. Shen S, Hatgus SJ, Martin BM, Pohl LR. Cytochrome P4502C11 is a target of diclofenac covalent binding in rats. Chem Res Toxicol 1997; 10: 420-423.
45. Maggi CA, Lualdi P, Mautone G. Comparative bioavailability of diclofenac hydroxyethylpyrrolidine vs diclofenac sodium in man. Eur J Clin Pharmacol 1990; 38: 207-208.
46. Tabata K, Yamaoka K, Fukuyama T, Nakagawa T. Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac. Pharm Res 1995; 12: 880-883.
47. Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 1979; 16: 405-410.